Erdafitinib Patent Expiration
Erdafitinib is Used for treating locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations that has progressed after prior systemic therapy. It was first introduced by Janssen Biotech Inc
Erdafitinib Patents
Given below is the list of patents protecting Erdafitinib, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Balversa | US10478494 | FGFR/PD-1 combination therapy for the treatment of cancer | Aug 13, 2036 | Janssen Biotech |
Balversa | US10898482 | Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine | Feb 09, 2036 | Janssen Biotech |
Balversa | US11077106 | Cancer treatment | Feb 02, 2038 | Janssen Biotech |
Balversa | US11684620 | Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine | Feb 09, 2036 | Janssen Biotech |
Balversa | US8895601 | Pyrazolyl quinoxaline kinase inhibitors | Apr 12, 2033 | Janssen Biotech |
Balversa | US9464071 | Pyrazolyl quinoxaline kinase inhibitors | Apr 28, 2031 | Janssen Biotech |
Balversa | US9902714 | Quinoxaline derivatives useful as FGFR kinase modulators | Mar 26, 2035 | Janssen Biotech |
Coming Soon
Patent Strength Analyzer
![](/_nuxt/img/PatentAnalyzerAd.722976d.jpg)
YesNo
Thank you for your response 🥳